{
  "success": true,
  "pagesUsed": [
    3,
    9,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    23,
    34,
    57
  ],
  "modelUsed": "claude-opus-4-5",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "Screening Window",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 28,
        "relativeTo": "Randomization",
        "windowLower": -28,
        "windowUpper": -2
      },
      {
        "id": "timing_2",
        "name": "Washout Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 3,
        "relativeTo": "Previous Visit",
        "windowLower": 3,
        "windowUpper": 14
      },
      {
        "id": "timing_3",
        "name": "Follow-up Visit Window",
        "type": "Within",
        "unit": "days",
        "instanceType": "Timing",
        "value": 28,
        "relativeTo": "Last Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_4",
        "name": "Post-Glucagon Discharge",
        "type": "After",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 6,
        "relativeTo": "First Dose",
        "windowLower": 0
      },
      {
        "id": "timing_5",
        "name": "Study Treatment Administration After Insulin Stop",
        "type": "After",
        "unit": "minutes",
        "instanceType": "Timing",
        "value": 5,
        "relativeTo": "Baseline",
        "windowLower": 0
      },
      {
        "id": "timing_6",
        "name": "Bedside PG Monitoring Interval (PG ≥90 mg/dL)",
        "type": "Within",
        "unit": "minutes",
        "instanceType": "Timing",
        "value": 10,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 10
      },
      {
        "id": "timing_7",
        "name": "Bedside PG Monitoring Interval (PG <90 mg/dL)",
        "type": "Within",
        "unit": "minutes",
        "instanceType": "Timing",
        "value": 5,
        "relativeTo": "Previous Visit",
        "windowLower": 0,
        "windowUpper": 5
      },
      {
        "id": "timing_8",
        "name": "Additional Follow-up for TE ADA",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 84,
        "relativeTo": "Last Dose",
        "windowLower": -7,
        "windowUpper": 7
      },
      {
        "id": "timing_9",
        "name": "Maximum TE ADA Follow-up Duration",
        "type": "Within",
        "unit": "years",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "Last Dose",
        "windowLower": 0,
        "windowUpper": 365
      },
      {
        "id": "timing_10",
        "name": "Fasting Requirement Before Study Procedures",
        "type": "Before",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 8,
        "relativeTo": "Study Start",
        "windowUpper": 0
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "Treatment Success Criteria",
        "instanceType": "Condition",
        "description": "Primary efficacy endpoint for treatment success",
        "text": "Plasma glucose increase of ≥20 mg/dL from baseline within 30 minutes of glucagon administration without additional rescue therapy"
      },
      {
        "id": "cond_2",
        "name": "Hypoglycemia Induction Target",
        "instanceType": "Condition",
        "description": "Target plasma glucose level for hypoglycemia induction",
        "text": "Bedside PG reaches <60 mg/dL"
      },
      {
        "id": "cond_3",
        "name": "Admission PG Criteria",
        "instanceType": "Condition",
        "description": "Plasma glucose level required for admission on Day 1",
        "text": "PG level is 90 to 250 mg/dL on Day 1"
      },
      {
        "id": "cond_4",
        "name": "TE ADA Resolution Criteria",
        "instanceType": "Condition",
        "description": "Criteria for completing additional immunogenicity follow-up",
        "text": "Titer returns to baseline (within a single 2-fold dilution of the baseline titer)"
      },
      {
        "id": "cond_5",
        "name": "Safety Review Criteria",
        "instanceType": "Condition",
        "description": "Safety data review requirement before continuing enrollment",
        "text": "Safety data will be reviewed after the first 6 patients are administered LY900018 in Period 2"
      },
      {
        "id": "cond_6",
        "name": "Evaluable Primary Outcome",
        "instanceType": "Condition",
        "description": "Minimum completers required for study",
        "text": "At least 66 patients (at least 30 patients with T1DM and T2DM, respectively) complete both periods with evaluable primary outcome"
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Screening to Period 1 Transition",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_screening",
        "toElementId": "epoch_period1",
        "text": "Patients will undergo a screening examination within 28 days prior to enrollment and be randomized to treatment sequence"
      },
      {
        "id": "trans_2",
        "name": "Period 1 to Washout Transition",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_period1",
        "toElementId": "epoch_washout",
        "text": "Patients complete Period 1 Day 1 procedures and may be discharged 6 hours after glucagon administration"
      },
      {
        "id": "trans_3",
        "name": "Washout to Period 2 Transition",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_washout",
        "toElementId": "epoch_period2",
        "text": "Periods 1 and 2 will be separated by a washout period of 3 to 14 days"
      },
      {
        "id": "trans_4",
        "name": "Period 2 to Follow-up Transition",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_period2",
        "toElementId": "epoch_followup",
        "text": "Patients will return for a follow-up visit 26 to 30 days after the last study treatment"
      },
      {
        "id": "trans_5",
        "name": "Insulin Infusion Stop Trigger",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "fromElementId": "procedure_insulin_infusion",
        "toElementId": "procedure_study_treatment",
        "text": "Insulin infusion is stopped once bedside PG is <60 mg/dL"
      },
      {
        "id": "trans_6",
        "name": "Admission Reschedule",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "visit_day_minus1",
        "toElementId": "visit_day_minus1",
        "text": "Admission can be rescheduled if PG level is not 90 to 250 mg/dL on Day 1"
      },
      {
        "id": "trans_7",
        "name": "Discontinuation for Other Study Enrollment",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Enrollment in any other clinical study involving an investigational product or enrollment in any other type of medical research judged not to be scientifically or medically compatible with this study"
      },
      {
        "id": "trans_8",
        "name": "Discontinuation for Medical/Safety/Regulatory Reasons",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participation in the study needs to be stopped for medical, safety, regulatory, or other reasons consistent with applicable laws, regulations, and good clinical practice"
      },
      {
        "id": "trans_9",
        "name": "Investigator Decision Discontinuation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "The investigator decides that the patient should be discontinued from the study for any reason"
      },
      {
        "id": "trans_10",
        "name": "Patient Decision Discontinuation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "The patient, or legal representative, requests to be withdrawn from the study"
      },
      {
        "id": "trans_11",
        "name": "TE ADA Additional Follow-up Trigger",
        "instanceType": "TransitionRule",
        "transitionType": "Epoch Transition",
        "fromElementId": "epoch_followup",
        "toElementId": "epoch_ada_followup",
        "text": "Patients with TE ADA at follow-up/ED will undergo additional follow-up every 12 weeks until titer returns to baseline or until 1 year after the last dose"
      },
      {
        "id": "trans_12",
        "name": "Rescue Therapy for Insufficient Response",
        "instanceType": "TransitionRule",
        "transitionType": "Rescue Therapy",
        "text": "Procedures for Insufficient Response to Glucagon Administration"
      },
      {
        "id": "trans_13",
        "name": "Inadvertently Enrolled Patient Continuation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "If the sponsor or investigator identifies a patient who did not meet enrollment criteria and was inadvertently enrolled, a discussion must occur between the Lilly CP/CRP and the investigator to determine if the patient may continue in the study"
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "Completion of both treatment periods and follow-up visit 26 to 30 days after the last study treatment"
      },
      {
        "id": "exit_2",
        "name": "Early Discontinuation - Other Study Enrollment",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Enrollment in any other clinical study involving an investigational product"
      },
      {
        "id": "exit_3",
        "name": "Early Discontinuation - Medical/Safety/Regulatory",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Participation stopped for medical, safety, regulatory, or other reasons"
      },
      {
        "id": "exit_4",
        "name": "Early Discontinuation - Investigator Decision",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Investigator decides patient should be discontinued for any reason"
      },
      {
        "id": "exit_5",
        "name": "Early Discontinuation - Patient Decision",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Patient or legal representative requests withdrawal from the study"
      },
      {
        "id": "exit_6",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Patient repeatedly fails to return for scheduled visits and is unable to be contacted by the study site"
      },
      {
        "id": "exit_7",
        "name": "Study Termination for Safety",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Following the review of the safety data from the first 6 patients to complete Period 2 Day 1, the study will be stopped if deemed necessary for patient safety"
      },
      {
        "id": "exit_8",
        "name": "Patient Replacement",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "If patients discontinue from the study before completion of both periods with evaluable primary outcome for any reason, the patient may be replaced up to 75 patients enrolled"
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Safety Review Decision Point",
        "timepointId": "pt_period2_day1_first6",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Safety data review after first 6 patients complete Period 2 Day 1 to determine if remaining patients can be dosed",
        "conditionIds": [
          "cond_5"
        ]
      },
      {
        "id": "dec_2",
        "name": "Admission Eligibility Decision",
        "timepointId": "pt_day1",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision to proceed with admission or reschedule based on PG level 90-250 mg/dL",
        "conditionIds": [
          "cond_3"
        ]
      },
      {
        "id": "dec_3",
        "name": "Insulin Infusion Stop Decision",
        "timepointId": "pt_hypoglycemia_induction",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision to stop insulin infusion when bedside PG reaches <60 mg/dL",
        "conditionIds": [
          "cond_2"
        ]
      },
      {
        "id": "dec_4",
        "name": "Patient Discharge Decision",
        "timepointId": "pt_post_glucagon",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point for patient discharge at least 6 hours after glucagon administration, may stay longer at investigator discretion"
      },
      {
        "id": "dec_5",
        "name": "TE ADA Follow-up Continuation Decision",
        "timepointId": "pt_followup",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision to continue additional immunogenicity follow-up based on TE ADA status",
        "conditionIds": [
          "cond_4"
        ]
      },
      {
        "id": "dec_6",
        "name": "Inadvertent Enrollment Decision",
        "timepointId": "pt_any",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision between Lilly CP/CRP and investigator on whether inadvertently enrolled patient may continue"
      }
    ],
    "summary": {
      "timingCount": 10,
      "conditionCount": 6,
      "transitionRuleCount": 13,
      "exitCount": 8
    }
  }
}